Nobuko Yasutake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nobuko Yasutake has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Hideaki Yahata
Department of Gynecology and Obstetrics, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
4 shared publications - Hidetaka Yamamoto
Department of Pathology and Oncology, Graduate School of Medicine, Dentistry & Pharmaceutical Science Okayama University Okayama Japan
4 shared publications - Kenzo Sonoda
Department of Gynecology Kyushu University Beppu Hospital Beppu Japan
4 shared publications - Rina Jiromaru
Department of Otorhinolaryngology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
3 shared publications - Yoshinao Oda
Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
3 shared publications - Kiyoko Kato
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Wiley in Histopathology
Distinct Rb expression pattern in HPV ‐associated neuroendocrine carcinomas of the uterine cervix
Aims: This study aimed to characterize high‐risk human papillomavirus (HR‐HPV) infection and the expression patterns of p16, Rb, p53 and cyclin D1 in uterine cervical neuroendocrine carcinomas (UCNECs). We also aimed to clarify the similarities and differences between UCNECs and pulmonary neuroendocrine carcinomas (NECs). Methods and results: We examined the expression patterns of p16, Rb, p53, and cyclin D1 by immunohistochemistry (IHC) and HR‐HPV infection by mRNA in situ hybridization (ISH) in 29 UCNEC cases, along with histological review. Ten pulmonary small cell neuroendocrine carcinomas (SCNECs) were included for comparison. Histologically, most UCNECs were SCNECs combined with adenocarcinoma or squamous cell carcinoma. HR‐HPV ISH was performed in 28 UCNEC cases; 27 (96%) were HPV‐positive and 1 (4%) was HPV‐negative. All HPV‐positive cases ( n = 27) showed p16 overexpression, partial Rb loss, a wildtype p53 pattern, and negative cyclin D1 expression. The single HPV‐negative case showed focal p16 positivity, retained Rb expression, a wildtype p53 pattern and positive cyclin D1 expression. In contrast, all 10 pulmonary SCNEC cases were negative for HR‐HPV and positive for p16, showing complete loss ( n = 9) or retained ( n = 1) Rb expression, and often aberrant p53 expression ( n = 8; 5 diffuse and 3 null). Conclusions: Most UCNECs are associated with HPV infection and characterized by p16 overexpression as well as partial loss of Rb. The Rb expression pattern differs between HPV‐positive UCNECs and HPV‐negative pulmonary NECs, suggesting the potential diagnostic utility of Rb as well as p16.
- 30 September 2026
- Published by Wiley in Histopathology
Open AccessDistinct Rb expression pattern in HPV ‐associated neuroendocrine carcinomas of the uterine cervix
Aims: This study aimed to characterize high‐risk human papillomavirus (HR‐HPV) infection and the expression patterns of p16, Rb, p53 and cyclin D1 in uterine cervical neuroendocrine carcinomas (UCNECs). We also aimed to clarify the similarities and differences between UCNECs and pulmonary neuroendocrine carcinomas (NECs). Methods and results: We examined the expression patterns of p16, Rb, p53, and cyclin D1 by immunohistochemistry (IHC) and HR‐HPV infection by mRNA in situ hybridization (ISH) in 29 UCNEC cases, along with histological review. Ten pulmonary small cell neuroendocrine carcinomas (SCNECs) were included for comparison. Histologically, most UCNECs were SCNECs combined with adenocarcinoma or squamous cell carcinoma. HR‐HPV ISH was performed in 28 UCNEC cases; 27 (96%) were HPV‐positive and 1 (4%) was HPV‐negative. All HPV‐positive cases ( n = 27) showed p16 overexpression, partial Rb loss, a wildtype p53 pattern, and negative cyclin D1 expression. The single HPV‐negative case showed focal p16 positivity, retained Rb expression, a wildtype p53 pattern and positive cyclin D1 expression. In contrast, all 10 pulmonary SCNEC cases were negative for HR‐HPV and positive for p16, showing complete loss ( n = 9) or retained ( n = 1) Rb expression, and often aberrant p53 expression ( n = 8; 5 diffuse and 3 null). Conclusions: Most UCNECs are associated with HPV infection and characterized by p16 overexpression as well as partial loss of Rb. The Rb expression pattern differs between HPV‐positive UCNECs and HPV‐negative pulmonary NECs, suggesting the potential diagnostic utility of Rb as well as p16.
- Open Access
- 22 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1003-1015
Claudin‐18 expression in gastric type adenocarcinoma and HPV ‐associated adenocarcinoma of the uterine cervix
Aims: Claudin‐18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43‐14A antibody, or about the gene expression of its isoforms in ECAs. Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high‐risk human papillomavirus (HR‐HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV‐independent adenocarcinomas (gastric type [GAS], n = 24; non‐GAS, n = 11) and 86 HPV‐associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non‐GASs and 2/86 (2%) HPV‐associated ECAs, with positivity defined as staining in ≥75% of tumour cells, as in gastric cancer. When a 5% cut‐off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non‐GASs and 6/86 (7%) HPV‐associated ECAs; CLDN18 expression was thus significantly associated with GAS histology ( P < 0.0001). Among the 6 cases of HPV‐associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV‐associated ECAs. Six of 22 (27%) CLDN18‐positive GASs were also positive for p16, but their other features—such as CLDN18 expression and the Rb preserved pattern—were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV‐associated ECAs. Conclusions: CLDN18 (43‐14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV‐associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV‐associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.
- 22 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1003-1015
Open AccessClaudin‐18 expression in gastric type adenocarcinoma and HPV ‐associated adenocarcinoma of the uterine cervix
Aims: Claudin‐18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43‐14A antibody, or about the gene expression of its isoforms in ECAs. Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high‐risk human papillomavirus (HR‐HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV‐independent adenocarcinomas (gastric type [GAS], n = 24; non‐GAS, n = 11) and 86 HPV‐associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non‐GASs and 2/86 (2%) HPV‐associated ECAs, with positivity defined as staining in ≥75% of tumour cells, as in gastric cancer. When a 5% cut‐off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non‐GASs and 6/86 (7%) HPV‐associated ECAs; CLDN18 expression was thus significantly associated with GAS histology ( P < 0.0001). Among the 6 cases of HPV‐associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV‐associated ECAs. Six of 22 (27%) CLDN18‐positive GASs were also positive for p16, but their other features—such as CLDN18 expression and the Rb preserved pattern—were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV‐associated ECAs. Conclusions: CLDN18 (43‐14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV‐associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV‐associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.
- Open Access
- 6 March 2024
- Published by Wiley in Histopathology
- Vol. 84 (7) , 1178-1191
Immunohistochemical p16 overexpression and Rb loss correlate with high‐risk human papillomavirus infection in endocervical adenocarcinomas
Aims: p16 is a sensitive surrogate marker for transcriptionally active high‐risk human papillomavirus (HR‐HPV) infection in endocervical adenocarcinoma (ECA); however, its specificity is not perfect.Methods and results: We examined p16 and Rb expressions by immunohistochemistry (IHC) and the transcriptionally active HR‐HPV infection by mRNA in‐situ hybridisation (ISH) with histological review in 108 ECA cases. Thirteen adenocarcinomas of endometrial or equivocal origin (six endometrioid and seven serous carcinomas) were compared as the control group. HR‐HPV was detected in 83 of 108 ECA cases (77%), including five HPV‐associated adenocarcinomas in situ and 78 invasive HPV‐associated adenocarcinomas. All 83 HPV‐positive cases showed consistent morphology, p16 positivity and partial loss pattern of Rb. Among the 25 cases of HPV‐independent adenocarcinoma, four (16%) were positive for p16, and of these four cases, three of 14 (21%) were gastric type adenocarcinomas and one of 10 (10%) was a clear cell type adenocarcinoma. All 25 HPV‐independent adenocarcinomas showed preserved expression of Rb irrespective of the p16 status. Similarly, all 13 cases of the control group were negative for HR‐HPV with preserved expression of Rb, even though six of 13 (46%) cases were positive for p16. Compared with p16 alone, the combination of p16 overexpression and Rb partial loss pattern showed equally excellent sensitivity (each 100%) and improved specificity (100 versus 73.6%) and positive predictive values (100 versus 89.2%) in the ECA and control groups. Furthermore, HR‐HPV infection correlated with better prognosis among invasive ECAs.Conclusions: The results suggest that the combined use of p16 and Rb IHC could be a reliable method to predict HR‐HPV infection in primary ECAs and mimics. This finding may contribute to prognostic prediction and therapeutic strategy.
- 6 March 2024
- Published by Wiley in Histopathology
- Vol. 84 (7) , 1178-1191
Open AccessImmunohistochemical p16 overexpression and Rb loss correlate with high‐risk human papillomavirus infection in endocervical adenocarcinomas
Aims: p16 is a sensitive surrogate marker for transcriptionally active high‐risk human papillomavirus (HR‐HPV) infection in endocervical adenocarcinoma (ECA); however, its specificity is not perfect.Methods and results: We examined p16 and Rb expressions by immunohistochemistry (IHC) and the transcriptionally active HR‐HPV infection by mRNA in‐situ hybridisation (ISH) with histological review in 108 ECA cases. Thirteen adenocarcinomas of endometrial or equivocal origin (six endometrioid and seven serous carcinomas) were compared as the control group. HR‐HPV was detected in 83 of 108 ECA cases (77%), including five HPV‐associated adenocarcinomas in situ and 78 invasive HPV‐associated adenocarcinomas. All 83 HPV‐positive cases showed consistent morphology, p16 positivity and partial loss pattern of Rb. Among the 25 cases of HPV‐independent adenocarcinoma, four (16%) were positive for p16, and of these four cases, three of 14 (21%) were gastric type adenocarcinomas and one of 10 (10%) was a clear cell type adenocarcinoma. All 25 HPV‐independent adenocarcinomas showed preserved expression of Rb irrespective of the p16 status. Similarly, all 13 cases of the control group were negative for HR‐HPV with preserved expression of Rb, even though six of 13 (46%) cases were positive for p16. Compared with p16 alone, the combination of p16 overexpression and Rb partial loss pattern showed equally excellent sensitivity (each 100%) and improved specificity (100 versus 73.6%) and positive predictive values (100 versus 89.2%) in the ECA and control groups. Furthermore, HR‐HPV infection correlated with better prognosis among invasive ECAs.Conclusions: The results suggest that the combined use of p16 and Rb IHC could be a reliable method to predict HR‐HPV infection in primary ECAs and mimics. This finding may contribute to prognostic prediction and therapeutic strategy.
- 26 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 235, 153920
Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcoma
- 26 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 235, 153920
Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcoma